Glioblastoma Clinical Trial
Official title:
Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma FDOPA PET-CT
It was previously shown that [18F]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.
Malignant gliomas are aggressive primary brain tumors that almost always lead to rapid
patient deterioration and death. Timely diagnosis of recurrent disease as well as accurate
monitoring of therapeutic responses is critically important in glioblastoma patients.
Despite introduction of new treatment approaches patient prognosis is poor with less than
half of the patients being progression-free during the first 6 months after diagnosis of
disease recurrence (6-month-progression-free survival rates of 46%).
The current diagnostic standard of care for diagnosing and monitoring brain tumors is
contrast-enhanced, multi-planar magnetic resonance imaging (MRI). However, the ability of MRI
for early detection of disease recurrence or progression is limited. Moreover, determination
of treatment responses is difficult since benign tissue changes after radiation and/or
chemotherapy can have the appearance of tumor recurrence or progression on MRI. Positron
emission tomography (PET) is an established imaging technique that utilizes small amounts of
radioactivity attached to very minimal amounts of substances (tracers) that are injected via
a hand or arm vein. These substances can track certain features of cancers that can be
visualized by using the PET-CT scanner. For instance, a number of different PET-tracers have
been used to study brain tumor metabolism and to detect primary or recurrent tumors. These
include tracers of glucose ([18F]FDG) and amino acid metabolism (e.g., [11C] methionine and
[18F]FDOPA). Metabolic imaging of brain tumors with amino acid analogues has advantages over
FDG. Since FDG assess glucose metabolism and the normal brain consumes a lot of glucose it
can be difficult to detect tumors against high glucose use of normal brain tissue. FDOPA has
been successfully used clinically for many years. The advantage of FDOPA is that normal brain
tissue consumes very little FDOPA. Thus, tumors can be seen easily against a low background
activity.
FDOPA PET imaging detects brain tumors with a very high accuracy and affects the management
of 40% of patients. However, its impact on patient outcome defined as survival, costs, and/or
quality of life has not been demonstrated.
Randomized trials are needed to evaluate the impact of PET on patient management and outcome.
We will determine this by randomizing patients with suspected recurrence of glioblastoma into
those who are managed using conventional diagnostic imaging versus those who will receive
conventional imaging plus FDOPA PET. Randomization is like flipping a coin. Patients will
have a 50% chance to undergo standard imaging or standard imaging combined with FDOPA PET.
Approximately 25-40% of the patients with suspected tumor recurrence will have
pseudo-progression on MRI (i.e., the images suggest that there is tumor recurrence when there
is in fact no recurrence). These patients will have correctly negative FDOPA PET scans. In
these patient initiation of treatment can be postponed. In contrast, patients with positive
FDOPA PET scans will undergo some kind of treatment at the discretion of the treating
physician (radiation therapy, chemotherapy or surgery). We will find out whether the
management and treatment change that is based on FDOPA PET affects the survival of patients
and affects the costs of caring for the patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
| Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
| Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
| Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
| Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
| Terminated |
NCT02905643 -
Discerning Pseudoprogression vs True Tumor Growth in GBMs
|